Economic Burden of Venous Thromboembolism in Hospitalized Patients
Key result
Venous thromboembolism imposes a significant economic burden on the US healthcare system, costing over $1.5 billion annually, highlighting the need for appropriate thromboprophylaxis programs.
Why the study?
What is the economic burden of venous thromboembolism and the impact of appropriate thromboprophylaxis in hospitalized patients?
Population
Hospitalized patients at risk for or with venous thromboembolism (deep vein thrombosis and pulmonary embolism)
Comparison
Venous thromboprophylaxis vs Failure to use appropriate prophylaxis
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May inform hospital budgeting; leaves open whether expanded prophylaxis programs reduce VTE costs in practice.
Structured PICO
What is the economic burden of venous thromboembolism and the impact of appropriate thromboprophylaxis in hospitalized patients?
P
Population
Hospitalized patients at risk for or with venous thromboembolism (deep vein thrombosis and pulmonary embolism)
I
Intervention
Venous thromboprophylaxis
C
Comparator
Failure to use appropriate prophylaxis
O
Outcome
Economic burden and costs associated with venous thromboembolism management
Venous thromboembolism imposes a massive economic burden on the US healthcare system, highlighting the critical need for appropriate thromboprophylaxis protocols in hospitals.
Cite This Study
Paul P. Dobesh (2009) conducted a review in Venous thromboembolism. Venous thromboembolism prophylaxis was evaluated. Venous thromboembolism imposes a significant economic burden on the US healthcare system, costing over $1.5 billion annually, highlighting the need for appropriate thromboprophylaxis programs.